RNA splicing dysregulation and the hallmarks of cancer.

Black, D. L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72, 291–336 (2003).

doi: 10.1146/annurev.biochem.72.121801.161720 pubmed: 12626338

Reixachs-Sole, M. & Eyras, E. Uncovering the impacts of alternative splicing on the proteome with current omics techniques. Wiley Interdiscip. Rev. RNA 13, e1707 (2022).

doi: 10.1002/wrna.1707 pubmed: 34979593 pmcid: 9542554

Blencowe, B. J. Alternative splicing: new insights from global analyses. Cell 126, 37–47 (2006).

doi: 10.1016/j.cell.2006.06.023 pubmed: 16839875

Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008). This landmark study uses RNA-seq to quantify isoform expression across tissues.

doi: 10.1038/nature07509 pubmed: 18978772 pmcid: 2593745

Kahles, A. et al. Comprehensive analysis of alternative splicing across tumors from 8705 patients. Cancer Cell 34, 211–224.e6 (2018). This landmark study identifies splicing alterations across tumour types.

doi: 10.1016/j.ccell.2018.07.001 pubmed: 30078747 pmcid: 9844097

Urbanski, L. M., Leclair, N. & Anczukow, O. Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip. Rev. RNA 9, 1476 (2018).

doi: 10.1002/wrna.1476

Dvinge, H., Kim, E., Abdel-Wahab, O. & Bradley, R. K. RNA splicing factors as oncoproteins and tumour suppressors. Nat. Rev. Cancer 16, 413–430 (2016).

doi: 10.1038/nrc.2016.51 pubmed: 27282250 pmcid: 5094465

Stanley, R. F. & Abdel-Wahab, O. Dysregulation and therapeutic targeting of RNA splicing in cancer. Nat. Cancer 3, 536–546 (2022).

doi: 10.1038/s43018-022-00384-z pubmed: 35624337 pmcid: 9551392

Bonnal, S. C., López-Oreja, I. & Valcárcel, J. Roles and mechanisms of alternative splicing in cancer—implications for care. Nat. Rev. Clin. Oncol. 17, 457–474 (2020).

doi: 10.1038/s41571-020-0350-x pubmed: 32303702

Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).

doi: 10.1158/2159-8290.CD-21-1059 pubmed: 35022204

Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).

doi: 10.1016/S0092-8674(00)81683-9 pubmed: 10647931

Wilkinson, M. E., Charenton, C. & Nagai, K. RNA splicing by the spliceosome. Annu. Rev. Biochem. 89, 359–388 (2020).

doi: 10.1146/annurev-biochem-091719-064225 pubmed: 31794245

Akinyi, M. V. & Frilander, M. J. At the intersection of major and minor spliceosomes: crosstalk mechanisms and their impact on gene expression. Front. Genet. 12, 700744 (2021).

doi: 10.3389/fgene.2021.700744 pubmed: 34354740 pmcid: 8329584

Lee, Y. & Rio, D. C. Mechanisms and regulation of alternative pre-mRNA splicing. Annu. Rev. Biochem. 84, 291–323 (2015).

doi: 10.1146/annurev-biochem-060614-034316 pubmed: 25784052 pmcid: 4526142

Ellis, J. D. et al. Tissue-specific alternative splicing remodels protein–protein interaction networks. Mol. Cell 46, 884–892 (2012).

doi: 10.1016/j.molcel.2012.05.037 pubmed: 22749401

Tung, K. F., Pan, C. Y., Chen, C. H. & Lin, W. C. Top-ranked expressed gene transcripts of human protein-coding genes investigated with GTEx dataset. Sci. Rep. 10, 16245 (2020).

doi: 10.1038/s41598-020-73081-5 pubmed: 33004865 pmcid: 7530651

Howard, J. M. & Sanford, J. R. The RNAissance family: SR proteins as multifaceted regulators of gene expression. Wiley Interdiscip. Rev. RNA 6, 93–110 (2015).

doi: 10.1002/wrna.1260 pubmed: 25155147

Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016).

doi: 10.1007/s00439-016-1683-5 pubmed: 27215579 pmcid: 4947485

Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).

doi: 10.1056/NEJMoa1103283 pubmed: 21995386 pmcid: 3322589

Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011).

doi: 10.1038/nature10496 pubmed: 21909114

Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133–135 (2013).

doi: 10.1038/ng.2523 pubmed: 23313955 pmcid: 3789378

Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933–936 (2013). Together with Harbour et al. (2013), this paper identifies recurrent mutations in SF3B1 in UVM.

doi: 10.1038/ng.2674 pubmed: 23793026 pmcid: 4307600

Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012).

doi: 10.1016/j.cell.2012.08.029 pubmed: 22980975 pmcid: 3557932

Lee, S. C. et al. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. Cancer Cell 34, 225–241.e8 (2018).

doi: 10.1016/j.ccell.2018.07.003 pubmed: 30107174 pmcid: 6373472

Taylor, J. et al. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood 136, 1477–1486 (2020).

doi: 10.1182/blood.2020006868 pubmed: 32640014 pmcid: 7515689

Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497–2506 (2011). This work identifies recurrent mutations in SF3B1 in CLL.

doi: 10.1056/NEJMoa1109016 pubmed: 22150006 pmcid: 3685413

Alsafadi, S. et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016).

doi: 10.1038/ncomms10615 pubmed: 26842708 pmcid: 4743009

Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3′ splice site selection through use of a different branch point. Cell Rep. 13, 1033–1045 (2015). This work demonstrates that recurrent SF3B1 mutations alter branch point selection.

doi: 10.1016/j.celrep.2015.09.053 pubmed: 26565915

Dalton, W. B. et al. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Adv. 4, 1192–1196 (2020).

doi: 10.1182/bloodadvances.2019001127 pubmed: 32211880 pmcid: 7160262

Inoue, D. et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574, 432–436 (2019). This work shows that SF3B1 mutations disrupt chromatin remodelling to promote tumorigenesis.

doi: 10.1038/s41586-019-1646-9 pubmed: 31597964 pmcid: 6858563

Lieu, Y. K. et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc. Natl Acad. Sci. USA 119, 2111703119 (2022).

doi: 10.1073/pnas.2111703119

Clough, C. A. et al. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome. Blood 139, 2038–2049 (2022).

doi: 10.1182/blood.2021012652 pubmed: 34861039

Yoshimi, A. et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature 574, 273–277 (2019). This work demonstrates genetic and functional interactions between SRSF2 and IDH2 in leukaemia.

doi: 10.1038/s41586-019-1618-0 pubmed: 31578525 pmcid: 6858560

Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220.e15 (2017).

doi: 10.1016/j.ccell.2017.07.003 pubmed: 28810145 pmcid: 5619925

Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27, 617–630 (2015).

doi: 10.1016/j.ccell.2015.04.006 pubmed: 25965569 pmcid: 4429920

Gallardo, M. et al. hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell 28, 486–499 (2015).

doi: 10.1016/j.ccell.2015.09.001 pubmed: 26412324 pmcid: 4652598

Graubert, T. A. et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 44, 53–57 (2012).

doi: 10.1038/ng.1031

Brooks, A. N. et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS ONE 9, 87361 (2014).

doi: 10.1371/journal.pone.0087361

Ilagan, J. O. et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 25, 14–26 (2015).

doi: 10.1101/gr.181016.114 pubmed: 25267526 pmcid: 4317169

Smith, M. A. et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat. Cell Biol. 21, 640–650 (2019).

doi: 10.1038/s41556-019-0314-5 pubmed: 31011167 pmcid: 6679973

Biancon, G. et al. Precision analysis of mutant U2AF1 activity reveals deployment of stress granules in myeloid malignancies. Mol. Cell 82, 1107–1122.e7 (2022).

doi: 10.1016/j.molcel.2022.02.025 pubmed: 35303483

Damm, F. et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 119, 3211–3218 (2012).

doi: 10.1182/blood-2011-12-400994 pubmed: 22343920

Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).

doi: 10.1038/leu.2013.336 pubmed: 24220272

Madan, V. et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat. Commun. 6, 6042 (2015).

doi: 10.1038/ncomms7042 pubmed: 25586593

Inoue, D. et al. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. Nat. Genet. 53, 707–718 (2021). This work shows that disruption of minor intron splicing by ZRSR2 mutations promotes clonal advantage.

doi: 10.1038/s41588-021-00828-9 pubmed: 33846634 pmcid: 8177065

Wang, X., Song, X. & Yan, X. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: a meta-analysis. Medicine 98, e15743 (2019).

doi: 10.1097/MD.0000000000015743 pubmed: 31124956 pmcid: 6571257

Obeng, E. A. et al. Physiologic expression of Sf3b1

doi: 10.1016/j.ccell.2016.08.006 pubmed: 27622333 pmcid: 5023069

Shirai, C. L. et al. Mutant U2AF1 expression alters hematopoiesis and pre-mRNA splicing in vivo. Cancer Cell 27, 631–643 (2015).

doi: 10.1016/j.ccell.2015.04.008 pubmed: 25965570 pmcid: 4430854

Fei, D. L. et al. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1. Proc. Natl Acad. Sci. USA 115, 10437–E10446 (2018).

doi: 10.1073/pnas.1812669115

Mian, S. A. et al. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat. Commun. 6, 10004 (2015). This work shows that SF3B1 mutations are initiating events in MDS.

doi: 10.1038/ncomms10004 pubmed: 26643973

Fabre, M. A. et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature 606, 335–342 (2022).

doi: 10.1038/s41586-022-04785-z pubmed: 35650444 pmcid: 9177423

Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).

doi: 10.1038/nature13385

Ibrahimpasic, T. et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clin. Cancer Res. 23, 5970–5980 (2017).

doi: 10.1158/1078-0432.CCR-17-1183 pubmed: 28634282 pmcid: 5626586

Anczuków, O. & Krainer, A. R. Splicing-factor alterations in cancers. RNA 22, 1285–1301 (2016).

doi: 10.1261/rna.057919.116 pubmed: 27530828 pmcid: 4986885

Seiler, M. et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 23, 282–296.e4 (2018).

doi: 10.1016/j.celrep.2018.01.088 pubmed: 29617667 pmcid: 5933844

Escobar-Hoyos, L. F. et al. Altered RNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer. Cancer Cell 38, 198–211.e8 (2020).

doi: 10.1016/j.ccell.2020.05.010 pubmed: 32559497 pmcid: 8028848

Anczukow, O. et al. The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19, 220–228 (2012).

doi: 10.1038/nsmb.2207 pubmed: 22245967 pmcid: 3272117

Anczukow, O. et al. SRSF1-regulated alternative splicing in breast cancer. Mol. Cell 60, 105–117 (2015).

doi: 10.1016/j.molcel.2015.09.005 pubmed: 26431027 pmcid: 4597910

Park, S. et al. Differential functions of splicing factors in mammary transformation and breast cancer metastasis. Cell Rep. 29, 2672–2688.e7 (2019). This work identifies the functional roles of individual SR proteins in breast cancer.

doi: 10.1016/j.celrep.2019.10.110 pubmed: 31775037 pmcid: 6936330

Karni, R. et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14, 185–193 (2007). This landmark study shows that SRSF1 is a proto-oncoprotein.

doi: 10.1038/nsmb1209 pubmed: 17310252 pmcid: 4595851

Sebestyén, E. et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. 26, 732–744 (2016).

doi: 10.1101/gr.199935.115 pubmed: 27197215 pmcid: 4889968

Ghigna, C. et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 20, 881–890 (2005).

doi: 10.1016/j.molcel.2005.10.026 pubmed: 16364913

Das, S., Anczukow, O., Akerman, M. & Krainer, A. R. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 1, 110–117 (2012).

doi: 10.1016/j.celrep.2011.12.001 pubmed: 22545246 pmcid: 3334311

De Miguel, F. J. et al. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 74, 1105–1115 (2014).

doi: 10.1158/0008-5472.CAN-13-1481 pubmed: 24371231

Michlewski, G., Sanford, J. R. & Caceres, J. F. The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1. Mol. Cell 30, 179–189 (2008).

doi: 10.1016/j.molcel.2008.03.013 pubmed: 18439897

Karni, R., Hippo, Y., Lowe, S. W. & Krainer, A. R. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc. Natl Acad. Sci. USA 105, 15323–15327 (2008).

doi: 10.1073/pnas.0801376105 pubmed: 18832178 pmcid: 2563124

Sen, S., Langiewicz, M., Jumaa, H. & Webster, N. J. Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology 61, 171–183 (2015).

doi: 10.1002/hep.27380 pubmed: 25132062

Ajiro, M., Jia, R., Yang, Y., Zhu, J. & Zheng, Z. M. A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells. Nucleic Acids Res. 44, 1854–1870 (2016).

doi: 10.1093/nar/gkv1500 pubmed: 26704980

Wang, Z. et al. Exon-centric regulation of pyruvate kinase M alternative splicing via mutually exclusive exons. J. Mol. Cell Biol. 4, 79–87 (2012).

doi: 10.1093/jmcb/mjr030 pubmed: 22044881

Kurokawa, K. et al. Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells. Oncogene 33, 1407–1417 (2014).

doi: 10.1038/onc.2013.86 pubmed: 23503458

Jia, R., Ajiro, M., Yu, L., McCoy, P. Jr & Zheng, Z. M. Oncogenic splicing factor SRSF3 regulates ILF3 alternative splicing to promote cancer cell proliferation and transformation. RNA 25, 630–644 (2019).

doi: 10.1261/rna.068619.118 pubmed: 30796096 pmcid: 6467003

Freytag, M. et al. Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. BMC Cancer 20, 1220 (2020).

doi: 10.1186/s12885-020-07682-8 pubmed: 33339518 pmcid: 7749503

Gokmen-Polar, Y. et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways. EMBO Rep. 20, 46078 (2019).

doi: 10.15252/embr.201846078

Shapiro, I. M. et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 7, 1002218 (2011).

doi: 10.1371/journal.pgen.1002218

Munkley, J. et al. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 8, 47678 (2019).

doi: 10.7554/eLife.47678

Ishii, H. et al. Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J. Biol. Chem. 289, 27386–27399 (2014).

doi: 10.1074/jbc.M114.589432 pubmed: 25143390 pmcid: 4183779

Bechara, E. G., Sebestyen, E., Bernardis, I., Eyras, E. & Valcarcel, J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 52, 720–733 (2013). This work demonstrates the role of RBMs in tumorigenesis.

doi: 10.1016/j.molcel.2013.11.010 pubmed: 24332178

Rintala-Maki, N. D. et al. Expression of RBM5-related factors in primary breast tissue. J. Cell Biochem. 100, 1440–1458 (2007).

doi: 10.1002/jcb.21134 pubmed: 17131366

Inoue, A. RBM10: structure, functions, and associated diseases. Gene 783, 145463 (2021).

doi: 10.1016/j.gene.2021.145463 pubmed: 33515724

Lu, W. et al. QKI impairs self-renewal and tumorigenicity of oral cancer cells via repression of SOX2. Cancer Biol. Ther. 15, 1174–1184 (2014).

doi: 10.4161/cbt.29502 pubmed: 24918581 pmcid: 4128860

Zong, F. Y. et al. The RNA-binding protein QKI suppresses cancer-associated aberrant splicing. PLoS Genet. 10, 1004289 (2014).

doi: 10.1371/journal.pgen.1004289

Bandopadhayay, P. et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat. Genet. 48, 273–282 (2016).

doi: 10.1038/ng.3500 pubmed: 26829751 pmcid: 4767685

Shirakihara, T. et al. TGF-β regulates isoform switching of FGF receptors and epithelial–mesenchymal transition. EMBO J. 30, 783–795 (2011).

doi: 10.1038/emboj.2010.351 pubmed: 21224849 pmcid: 3041949

Warzecha, C. C. et al. An ESRP-regulated splicing programme is abrogated during the epithelial–mesenchymal transition. EMBO J. 29, 3286–3300 (2010). This work demonstrates the important role played by regulated splicing during EMT.

doi: 10.1038/emboj.2010.195 pubmed: 20711167 pmcid: 2957203

Warzecha, C. C., Shen, S., Xing, Y. & Carstens, R. P. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol. 6, 546–562 (2009).

doi: 10.4161/rna.6.5.9606 pubmed: 19829082

Yae, T. et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun. 3, 883 (2012). This work demonstrates the role of a CD44 isoform in lung metastasis in vivo.

doi: 10.1038/ncomms1892 pubmed: 22673910

Sutherland, L. C., Wang, K. & Robinson, A. G. RBM5 as a putative tumor suppressor gene for lung cancer. J. Thorac. Oncol. 5, 294–298 (2010).

doi: 10.1097/JTO.0b013e3181c6e330 pubmed: 20186023

Jamsai, D. et al. In vivo evidence that RBM5 is a tumour suppressor in the lung. Sci. Rep. 7, 16323 (2017).

doi: 10.1038/s41598-017-15874-9 pubmed: 29176597 pmcid: 5701194

Zhao, Y. et al. The tumor suppressing effects of QKI-5 in prostate cancer: a novel diagnostic and prognostic protein. Cancer Biol. Ther. 15, 108–118 (2014).

doi: 10.4161/cbt.26722 pubmed: 24153116

Frampton, G. M. et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 5, 850–859 (2015).

doi: 10.1158/2159-8290.CD-15-0285 pubmed: 25971938

Jung, H. et al. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat. Genet. 47, 1242–1248 (2015).

doi: 10.1038/ng.3414 pubmed: 26437032

Mogilevsky, M. et al. Modulation of MKNK2 alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment. Nucleic Acids Res. 46, 11396–11404 (2018).

doi: 10.1093/nar/gky921 pubmed: 30329087 pmcid: 6265459

Koh, C. M. et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 523, 96–100 (2015). This work identifies a MYC-driven splicing vulnerability.

doi: 10.1038/nature14351 pubmed: 25970242

Ben-Hur, V. et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 3, 103–115 (2013).

doi: 10.1016/j.celrep.2012.11.020 pubmed: 23273915

Amaral, C. L. et al. S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells. BMC Cancer 16, 602 (2016).

doi: 10.1186/s12885-016-2629-y pubmed: 27491285 pmcid: 4974797

Mei, H., Wang, Y., Fan, J. & Lin, Z. Alternative splicing of S6K1 promotes non-small cell lung cancer survival. Tumour Biol. 37, 13369–13376 (2016).

doi: 10.1007/s13277-016-5253-1 pubmed: 27460085

David, C. J., Chen, M., Assanah, M., Canoll, P. & Manley, J. L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364–368 (2010).

doi: 10.1038/nature08697 pubmed: 20010808

Clower, C. V. et al. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc. Natl Acad. Sci. USA 107, 1894–1899 (2010).

doi: 10.1073/pnas.0914845107 pubmed: 20133837 pmcid: 2838216

Dayton, T. L., Jacks, T. & Vander Heiden, M. G. PKM2, cancer metabolism, and the road ahead. EMBO Rep. 17, 1721–1730 (2016).

doi: 10.15252/embr.201643300 pubmed: 27856534 pmcid: 5283597

Wang, Z., Jeon, H. Y., Rigo, F., Bennett, C. F. & Krainer, A. R. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open. Biol. 2, 120133 (2012).

doi: 10.1098/rsob.120133 pubmed: 23155487 pmcid: 3498831

Boise, L. H. et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597–608 (1993).

doi: 10.1016/0092-8674(93)90508-N pubmed: 8358789

Wu, L., Mao, C. & Ming, X. Modulation of Bcl-x alternative splicing induces apoptosis of human hepatic stellate cells. Biomed. Res. Int. 2016, 7478650 (2016).

pubmed: 27579319 pmcid: 4992517

Dole, M. G. et al. Bcl-xS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Cancer Res. 56, 5734–5740 (1996).

pubmed: 8971184

Minn, A. J., Boise, L. H. & Thompson, C. B. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J. Biol. Chem. 271, 6306–6312 (1996).

doi: 10.1074/jbc.271.11.6306 pubmed: 8626425

Paronetto, M. P., Achsel, T., Massiello, A., Chalfant, C. E. & Sette, C. The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J. Cell Biol. 176, 929–939 (2007).

doi: 10.1083/jcb.200701005 pubmed: 17371836 pmcid: 2064079

Zhou, A., Ou, A. C., Cho, A., Benz, E. J. Jr & Huang, S. C. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5′ splice site selection. Mol. Cell Biol. 28, 5924–5936 (2008).

doi: 10.1128/MCB.00560-08 pubmed: 18663000 pmcid: 2546994

Bielli, P., Bordi, M., Di Biasio, V. & Sette, C. Regulation of BCL-X splicing reveals a role for the polypyrimidine tract binding protein (PTBP1/hnRNP I) in alternative 5′ splice site selection. Nucleic Acids Res. 42, 12070–12081 (2014).

doi: 10.1093/nar/gku922 pubmed: 25294838 pmcid: 4231771

Wang, Y. et al. The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell 26, 374–389 (2014). This work demonstrates the role of RBMs in tumorigenesis in vivo.

doi: 10.1016/j.ccr.2014.07.010 pubmed: 25203323 pmcid: 4159621

Moore, M. J., Wang, Q., Kennedy, C. J. & Silver, P. A. An alternative splicing network links cell-cycle control to apoptosis. Cell 142, 625–636 (2010).

doi: 10.1016/j.cell.2010.07.019 pubmed: 20705336 pmcid: 2924962

Garneau, D., Revil, T., Fisette, J. F. & Chabot, B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J. Biol. Chem. 280, 22641–22650 (2005).

doi: 10.1074/jbc.M501070200 pubmed: 15837790

Revil, T., Pelletier, J., Toutant, J., Cloutier, A. & Chabot, B. Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform. J. Biol. Chem. 284, 21458–21467 (2009).

doi: 10.1074/jbc.M109.019711 pubmed: 19520842 pmcid: 2755870

Cloutier, P. et al. Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. J. Biol. Chem. 283, 21315–21324 (2008).

doi: 10.1074/jbc.M800353200 pubmed: 18534987

Pabla, N., Bhatt, K. & Dong, Z. Checkpoint kinase 1 (Chk1)-short is a splice variant and endogenous inhibitor of Chk1 that regulates cell cycle and DNA damage checkpoints. Proc. Natl Acad. Sci. USA 109, 197–202 (2012).

doi: 10.1073/pnas.1104767109 pubmed: 22184239

Hu, G. et al. Clinical and functional significance of CHK1-S, an alternatively spliced isoform of the CHK1 gene, in hepatocellular carcinoma. J. Cancer 11, 1792–1799 (2020).

doi: 10.7150/jca.39443 pubmed: 32194790 pmcid: 7052871

Wong, M. S., Shay, J. W. & Wright, W. E. Regulation of human telomerase splicing by RNA:RNA pairing. Nat. Commun. 5, 3306 (2014).

doi: 10.1038/ncomms4306 pubmed: 24577044

Sayed, M. E. et al. NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells. Oncogene 38, 2937–2952 (2019).

doi: 10.1038/s41388-018-0639-8 pubmed: 30568224

Ludlow, A. T. et al. NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat. Commun. 9, 3112 (2018).

doi: 10.1038/s41467-018-05582-x pubmed: 30082712 pmcid: 6079032

Listerman, I., Sun, J., Gazzaniga, F. S., Lukas, J. L. & Blackburn, E. H. The major reverse transcriptase-incompetent splice variant of the human telomerase protein inhibits telomerase activity but protects from apoptosis. Cancer Res. 73, 2817–2828 (2013).

doi: 10.1158/0008-5472.CAN-12-3082 pubmed: 23610451 pmcid: 3643995

Pont, A. R., Sadri, N., Hsiao, S. J., Smith, S. & Schneider, R. J. mRNA decay factor AUF1 maintains normal aging, telomere maintenance, and suppression of senescence by activation of telomerase transcription. Mol. Cell 47, 5–15 (2012).

doi: 10.1016/j.molcel.2012.04.019 pubmed: 22633954 pmcid: 3966316

Kang, X., Chen, W., Kim, R. H., Kang, M. K. & Park, N. H. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene 28, 565–574 (2009).

doi: 10.1038/onc.2008.404 pubmed: 19015635

DiFeo, A., Martignetti, J. A. & Narla, G. The role of KLF6 and its splice variants in cancer therapy. Drug. Resist. Updat. 12, 1–7 (2009).

doi: 10.1016/j.drup.2008.11.001 pubmed: 19097929

Hatami, R. et al. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Sci. Transl. Med. 5, 12 (2013).

doi: 10.1126/scitranslmed.3004688

Yea, S. et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134, 1521–1531 (2008).

doi: 10.1053/j.gastro.2008.02.015 pubmed: 18471523

Botella, L. M. et al. TGF-β regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3–Sp1–KLF6 interaction. Biochem. J. 419, 485–495 (2009).

doi: 10.1042/BJ20081434 pubmed: 19076057

DiFeo, A. et al. A functional role for KLF6–SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 68, 965–970 (2008).

doi: 10.1158/0008-5472.CAN-07-2604 pubmed: 18250346 pmcid: 2826216

Tanaka, N., Yoshida, H., Suzuki, Y. & Harigaya, K. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma. Int. J. Oncol. 45, 1921–1928 (2014).

doi: 10.3892/ijo.2014.2591 pubmed: 25109497

Oudin, M. J. et al. Characterization of the expression of the pro-metastatic Mena

doi: 10.1007/s10585-015-9775-5 pubmed: 26680363

Goswami, S. et al. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin. Exp. Metastasis 26, 153–159 (2009).

doi: 10.1007/s10585-008-9225-8 pubmed: 18985426

Di Modugno, F. et al. Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc. Natl Acad. Sci. USA 109, 19280–19285 (2012).

doi: 10.1073/pnas.1214394109 pubmed: 23129656 pmcid: 3511125

Bria, E. et al. Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. Oncotarget 5, 11054–11063 (2014).

doi: 10.18632/oncotarget.2609 pubmed: 25373410 pmcid: 4294370

Balsamo, M. et al. The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. Sci. Rep. 6, 35298 (2016).

doi: 10.1038/srep35298 pubmed: 27748415 pmcid: 5066228

Di Modugno, F. et al. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res. 67, 2657–2665 (2007).

doi: 10.1158/0008-5472.CAN-06-1997 pubmed: 17363586 pmcid: 3156572

Philippar, U. et al. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev. Cell 15, 813–828 (2008). This work identifies MENA isoforms.

doi: 10.1016/j.devcel.2008.09.003 pubmed: 19081071 pmcid: 2637261

Houck, K. A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806–1814 (1991).

doi: 10.1210/mend-5-12-1806 pubmed: 1791831

Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123–4131 (2002). This work identifies VEGF isoforms.

pubmed: 12124351

Woolard, J. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822–7835 (2004).

doi: 10.1158/0008-5472.CAN-04-0934 pubmed: 15520188

Nowak, D. G. et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J. Biol. Chem. 285, 5532–5540 (2010).

doi: 10.1074/jbc.M109.074930 pubmed: 19906640

Harper, S. J. & Bates, D. O. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer 8, 880–887 (2008).

doi: 10.1038/nrc2505 pubmed: 18923433 pmcid: 2613352

Pritchard-Jones, R. O. et al. Expression of VEGF

doi: 10.1038/sj.bjc.6603839 pubmed: 17595666 pmcid: 2360298

Varey, A. H. et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer 98, 1366–1379 (2008).

doi: 10.1038/sj.bjc.6604308 pubmed: 18349829 pmcid: 2361696

Biselli-Chicote, P. M. et al. Overexpression of antiangiogenic vascular endothelial growth factor isoform and splicing pegulatory factors in oral, laryngeal and pharyngeal squamous cell carcinomas. Asian Pac. J. Cancer Prev. 18, 2171–2177 (2017).

pubmed: 28843252 pmcid: 5697477

Rennel, E. et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br. J. Cancer 98, 1250–1257 (2008).

doi: 10.1038/sj.bjc.6604309 pubmed: 18349828 pmcid: 2359649

Robertson, C. The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking. Exp. Cell Res. 343, 73–81 (2016).

doi: 10.1016/j.yexcr.2015.11.009 pubmed: 26597760

Nam, J. M., Onodera, Y., Bissell, M. J. & Park, C. C. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin α5β1 and fibronectin. Cancer Res. 70, 5238–5248 (2010).

doi: 10.1158/0008-5472.CAN-09-2319 pubmed: 20516121 pmcid: 2933183

Schiefner, A., Gebauer, M. & Skerra, A. Extra-domain B in oncofetal fibronectin structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein. J. Biol. Chem. 287, 17578–17588 (2012).

doi: 10.1074/jbc.M111.303131 pubmed: 22442152 pmcid: 3366777

Fukuda, T. et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 62, 5603–5610 (2002).

pubmed: 12359774

Borsi, L. et al. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int. J. Cancer 52, 688–692 (1992).

doi: 10.1002/ijc.2910520504 pubmed: 1385335

Briones-Orta, M. A. et al. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim. Biophys. Acta 1868, 93–108A (2017).

Srebrow, A., Blaustein, M. & Kornblihtt, A. R. Regulation of fibronectin alternative splicing by a basement membrane-like extracellular matrix. FEBS Lett. 514, 285–289 (2002).

doi: 10.1016/S0014-5793(02)02382-7 pubmed: 11943167

Bordeleau, F. et al. Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors. Proc. Natl Acad. Sci. USA 112, 8314–8319 (2015).

doi: 10.1073/pnas.1505421112 pubmed: 26106154 pmcid: 4500261

Martinez, N. M. & Lynch, K. W. Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol. Rev. 253, 216–236 (2013).

doi: 10.1111/imr.12047 pubmed: 23550649 pmcid: 3621013

O’Connor, B. P. et al. Regulation of Toll-like receptor signaling by the SF3a mRNA splicing complex. PLoS Genet. 11, 1004932 (2015).

doi: 10.1371/journal.pgen.1004932

Adib-Conquy, M. et al. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit. Care Med. 34, 2377–2385 (2006).

doi: 10.1097/01.CCM.0000233875.93866.88 pubmed: 16850005

De Arras, L. et al. Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity. Genetics 197, 485–496 (2014).

doi: 10.1534/genetics.113.160499 pubmed: 24361939

Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011).

doi: 10.1038/nature10662 pubmed: 22113612 pmcid: 3266695

Wang, Y. et al. The BRCA1- Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 76, 2778–2790 (2016).

doi: 10.1158/0008-5472.CAN-16-0186 pubmed: 27197267 pmcid: 4874568

Ozden, O. et al. Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer. Sci. Rep. 6, 26273 (2016).

doi: 10.1038/srep26273 pubmed: 27197561 pmcid: 4873788

Ng, K. P. et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 18, 521–528 (2012). This work links resistance to tyrosine kinase inhibitors with BIM splicing.

doi: 10.1038/nm.2713 pubmed: 22426421

Castiglioni, F. et al. Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer 13, 221–232 (2006).

doi: 10.1677/erc.1.01047 pubmed: 16601290

Alajati, A. et al. Mammary tumor formation and metastasis evoked by a HER2 splice variant. Cancer Res. 73, 5320–5327 (2013).

doi: 10.1158/0008-5472.CAN-12-3186 pubmed: 23867476

Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469–5477 (2008). This work identifies a constitutively active AR isoform that contributes to therapy resistance.

doi: 10.1158/0008-5472.CAN-08-0594 pubmed: 18593950 pmcid: 2663383

Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).

doi: 10.1056/NEJMoa1315815 pubmed: 25184630 pmcid: 4201502

Sun, S. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715–2730 (2010). This work identifies a constitutively active AR isoform that contributes to castration resistance.

doi: 10.1172/JCI41824 pubmed: 20644256 pmcid: 2912187

Thiebaut, C. et al. The role of ERα36 in development and tumor malignancy. Int. J. Mol. Sci. 21, 4116 (2020).

doi: 10.3390/ijms21114116 pubmed: 32526980 pmcid: 7312586

Zheng, S., Asnani, M. & Thomas-Tikhonenko, A. Escape from ALL-CARTaz: leukemia immunoediting in the age of chimeric antigen receptors. Cancer J. 25, 217–222 (2019).

doi: 10.1097/PPO.0000000000000381 pubmed: 31135529 pmcid: 6617517

Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 5, 1282–1295 (2015). This work demonstrates that alternative splicing can enable escape from CAR T cell therapy.

doi: 10.1158/2159-8290.CD-15-1020 pubmed: 26516065 pmcid: 4670800

Zheng, S. et al. Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies. Blood Cancer Discov. 3, 103–115 (2022).

doi: 10.1158/2643-3230.BCD-21-0087 pubmed: 35015683 pmcid: 9780083

Nakajima, H. et al. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J. Antibiot. 49, 1204–1211 (1996).

doi: 10.7164/antibiotics.49.1204

Thompson, C. F., Jamison, T. F. & Jacobsen, E. N. FR901464: total synthesis, proof of structure, and evaluation of synthetic analogues. J. Am. Chem. Soc. 123, 9974–9983 (2001).

doi: 10.1021/ja016615t pubmed: 11592876

Kaida, D. et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat. Chem. Biol. 3, 576–583 (2007).

doi: 10.1038/nchembio.2007.18 pubmed: 17643111

Osman, S. et al. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. Chemistry 17, 895–904 (2011).

doi: 10.1002/chem.201002402 pubmed: 21226105

Albert, B. J., Sivaramakrishnan, A., Naka, T., Czaicki, N. L. & Koide, K. Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. J. Am. Chem. Soc. 129, 2648–2659 (2007).

doi: 10.1021/ja067870m pubmed: 17279752 pmcid: 2530894

Liu, X. et al. Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. J. Nat. Prod. 76, 685–693 (2013).

doi: 10.1021/np300913h pubmed: 23517093 pmcid: 3696399

Corrionero, A., Minana, B. & Valcarcel, J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes. Dev. 25, 445–459 (2011). This work characterizes the mechanism of action of spliceostatin A.

doi: 10.1101/gad.2014311 pubmed: 21363963 pmcid: 3049286

Seiler, M. et al. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nat. Med. 24, 497–504 (2018).

doi: 10.1038/nm.4493 pubmed: 29457796 pmcid: 6730556

Hong, D. S. et al. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest. N. Drugs 32, 436–444 (2014).

doi: 10.1007/s10637-013-0046-5

Eskens, F. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors. Clin. Cancer Res. 19, 6296–6304 (2013).

doi: 10.1158/1078-0432.CCR-13-0485 pubmed: 23983259

Steensma, D. P. et al. Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia 35, 3542–3550 (2021).

doi: 10.1038/s41375-021-01328-9 pubmed: 34172893 pmcid: 8632688

O’Brien, K., Matlin, A. J., Lowell, A. M. & Moore, M. J. The biflavonoid isoginkgetin is a general inhibitor of pre-mRNA splicing. J. Biol. Chem. 283, 33147–33154 (2008).

doi: 10.1074/jbc.M805556200 pubmed: 18826947 pmcid: 2586251

Vanzyl, E. J. et al. The spliceosome inhibitors isoginkgetin and pladienolide B induce ATF3-dependent cell death. PLoS ONE 15, e0224953 (2020).

doi: 10.1371/journal.pone.0224953 pubmed: 33370278 pmcid: 7769279

Yoon, S. O., Shin, S., Lee, H. J., Chun, H. K. & Chung, A. S. Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. Mol. Cancer Ther. 5, 2666–2675 (2006).

doi: 10.1158/1535-7163.MCT-06-0321 pubmed: 17121913

Darrigrand, R. et al. Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens. Commun. Biol. 4, 269 (2021).

doi: 10.1038/s42003-021-01801-2 pubmed: 33649389 pmcid: 7921396

Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 356, 3755 (2017). This work identifies RBM39 as the molecular target of indisulam.

doi: 10.1126/science.aal3755

Ting, T. C. et al. Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4–DCAF15. Cell Rep. 29, 1499–1510.e6 (2019).

doi: 10.1016/j.celrep.2019.09.079 pubmed: 31693891 pmcid: 7950731

Bussiere, D. E. et al. Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat. Chem. Biol. 16, 15–23 (2020).

doi: 10.1038/s41589-019-0411-6 pubmed: 31819272

Tari, M. et al. U2AF

doi: 10.15252/embr.201847604

Stepanyuk, G. A. et al. UHM–ULM interactions in the RBM39–U2AF65 splicing-factor complex. Acta Crystallogr. D. Struct. Biol. 72, 497–511 (2016).

doi: 10.1107/S2059798316001248 pubmed: 27050129 pmcid: 4822562

Loerch, S., Maucuer, A., Manceau, V., Green, M. R. & Kielkopf, C. L. Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex. J. Biol. Chem. 289, 17325–17337 (2014).

doi: 10.1074/jbc.M114.558825 pubmed: 24795046 pmcid: 4067167

Kralovicova, J. et al. PUF60-activated exons uncover altered 3′ splice-site selection by germline missense mutations in a single RRM. Nucleic Acids Res. 46, 6166–6187 (2018).

doi: 10.1093/nar/gky389 pubmed: 29788428 pmcid: 6093180

Mai, S. et al. Global regulation of alternative RNA splicing by the SR-rich protein RBM39. Biochim. Biophys. Acta 1859, 1014–1024 (2016).

doi: 10.1016/j.bbagrm.2016.06.007 pubmed: 27354116

Xu, Y., Nijhuis, A. & Keun, H. C. RNA-binding motif protein 39 (RBM39): an emerging cancer target. Br. J. Pharmacol. 179, 2795–2812 (2020).

doi: 10.1111/bph.15331

Hamid, O. et al. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. Cancer 120, 2016–2024 (2014).

doi: 10.1002/cncr.28635 pubmed: 24676877

Bezzi, M. et al. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev. 27, 1903–1916 (2013).

doi: 10.1101/gad.219899.113 pubmed: 24013503 pmcid: 3778243

Radzisheuskaya, A. et al. PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia. Nat. Struct. Mol. Biol. 26, 999–1012 (2019).

doi: 10.1038/s41594-019-0313-z pubmed: 31611688 pmcid: 6858565

Fong, J. Y. et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell 36, 194–209.e9 (2019).

doi: 10.1016/j.ccell.2019.07.003 pubmed: 31408619 pmcid: 7194031

Gammons, M. V. et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest. Ophthalmol. Vis. Sci. 54, 6052–6062 (2013).

doi: 10.1167/iovs.13-12422 pubmed: 23887803 pmcid: 3771558

Hatcher, J. M. et al. SRPKIN-1: a covalent SRPK1/2 inhibitor that potently converts VEGF from pro-angiogenic to anti-angiogenic isoform. Cell Chem. Biol. 25, 460–470.e6 (2018).

doi: 10.1016/j.chembiol.2018.01.013 pubmed: 29478907 pmcid: 5973797

Batson, J. et al. Development of potent, selective SRPK1 inhibitors as potential topical therapeutics for neovascular eye disease. ACS Chem. Biol. 12, 825–832 (2017).

doi: 10.1021/acschembio.6b01048 pubmed: 28135068

Sakuma, M., Iida, K. & Hagiwara, M. Deciphering targeting rules of splicing modulator compounds: case of TG003. BMC Mol. Biol. 16, 16 (2015).

doi: 10.1186/s12867-015-0044-6 pubmed: 26400733 pmcid: 4580995

Babu, N. et al. Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric Cancer 23, 796–810 (2020).

doi: 10.1007/s10120-020-01062-8 pubmed: 32333232

Uzor, S. et al. CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Sci. Rep. 11, 7963 (2021).

doi: 10.1038/s41598-021-86908-6 pubmed: 33846420 pmcid: 8041776

Sohail, M. et al. A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells. Nar. Cancer 3, 19 (2021).

doi: 10.1093/narcan/zcab019

Hluchy, M. et al. CDK11 regulates pre-mRNA splicing by phosphorylation of SF3B1. Nature 609, 829–834 (2022).

doi: 10.1038/s41586-022-05204-z pubmed: 36104565

Sheridan, C. First small-molecule drug targeting RNA gains momentum. Nat. Biotechnol. 39, 6–8 (2021).

doi: 10.1038/s41587-020-00788-1 pubmed: 33432225

Baranello, G. et al. Risdiplam in type 1 spinal muscular atrophy. N. Engl. J. Med. 384, 915–923 (2021). This work demonstrates that risdiplam increases SMN protein levels in patients with spinal muscular atrophy.

doi: 10.1056/NEJMoa2009965 pubmed: 33626251

Sivaramakrishnan, M. et al. Binding to SMN2 pre-mRNA–protein complex elicits specificity for small molecule splicing modifiers. Nat. Commun. 8, 1476 (2017).

doi: 10.1038/s41467-017-01559-4 pubmed: 29133793 pmcid: 5684323

Costales, M. G., Childs-Disney, J. L., Haniff, H. S. & Disney, M. D. How we think about targeting RNA with small molecules. J. Med. Chem. 63, 8880–8900 (2020).

doi: 10.1021/acs.jmedchem.9b01927 pubmed: 32212706 pmcid: 7486258

Umuhire Juru, A. & Hargrove, A. E. Frameworks for targeting RNA with small molecules. J. Biol. Chem. 296, 100191 (2021).

doi: 10.1074/jbc.REV120.015203 pubmed: 33334887

Havens, M. A. & Hastings, M. L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 44, 6549–6563 (2016).

doi: 10.1093/nar/gkw533 pubmed: 27288447 pmcid: 5001604

Bennett, C. F. & Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259–293 (2010).

doi: 10.1146/annurev.pharmtox.010909.105654 pubmed: 20055705

Kim, Y. et al. Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular cancer models. Mol. Ther. 27, 1547–1557 (2019).

doi: 10.1016/j.ymthe.2019.06.009 pubmed: 31303442 pmcid: 6731179

Scharner, J., Qi, S., Rigo, F., Bennett, C. F. & Krainer, A. R. Delivery of GalNAc-conjugated splice-switching ASOs to non-hepatic cells through ectopic expression of asialoglycoprotein receptor. Mol. Ther. Nucleic Acids 16, 313–325 (2019).

doi: 10.1016/j.omtn.2019.02.024 pubmed: 30965276 pmcid: 6453860

Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518–6548 (2016).

doi: 10.1093/nar/gkw236 pubmed: 27084936 pmcid: 5001581

Li, Z. et al. Pro-apoptotic effects of splice-switching oligonucleotides targeting Bcl-x pre-mRNA in human glioma cell lines. Oncol. Rep. 35, 1013–1019 (2016).

doi: 10.3892/or.2015.4465 pubmed: 26718027

Sun, Y., Yan, L., Guo, J., Shao, J. & Jia, R. Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment. Cancer Chemother. Pharmacol. 84, 1133–1143 (2019).

doi: 10.1007/s00280-019-03945-9 pubmed: 31515668

Leclair, N. K. et al. Poison exon splicing regulates a coordinated network of SR protein expression during differentiation and tumorigenesis. Mol. Cell 80, 648–665.e9 (2020). This work identifies functional roles for poison exons in tumorigenesis.

doi: 10.1016/j.molcel.2020.10.019 pubmed: 33176162 pmcid: 7680420

Denichenko, P. et al. Specific inhibition of splicing factor activity by decoy RNA oligonucleotides. Nat. Commun. 10, 1590 (2019).

doi: 10.1038/s41467-019-09523-0 pubmed: 30962446 pmcid: 6453957

Gadgil, A. & Raczynska, K. D. U7 snRNA: a tool for gene therapy. J. Gene Med. 23, 3321 (2021).

doi: 10.1002/jgm.3321

Rogalska, M. E. et al. Therapeutic activity of modified U1 core spliceosomal particles. Nat. Commun. 7, 11168 (2016).

doi: 10.1038/ncomms11168 pubmed: 27041075 pmcid: 4822034

Wang, Y., Cheong, C. G., Hall, T. M. & Wang, Z. Engineering splicing factors with designed specificities. Nat. Methods 6, 825–830 (2009).

doi: 10.1038/nmeth.1379 pubmed: 19801992 pmcid: 2963066

Cox, D. B. T. et al. RNA editing with CRISPR–Cas13. Science 358, 1019–1027 (2017).

doi: 10.1126/science.aaq0180 pubmed: 29070703 pmcid: 5793859

Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665–676.e14 (2018). This work uses RNA-targeting Cas to manipulate alternative splicing.

doi: 10.1016/j.cell.2018.02.033 pubmed: 29551272 pmcid: 5910255

Du, M., Jillette, N., Zhu, J. J., Li, S. & Cheng, A. W. CRISPR artificial splicing factors. Nat. Commun. 11, 2973 (2020).

doi: 10.1038/s41467-020-16806-4 pubmed: 32532987 pmcid: 7293279

Gapinske, M. et al. CRISPR–SKIP: programmable gene splicing with single base editors. Genome Biol. 19, 107 (2018).

doi: 10.1186/s13059-018-1482-5 pubmed: 30107853 pmcid: 6092781

Banas, K. et al. Exon skipping induced by CRISPR-directed gene editing regulates the response to chemotherapy in non-small cell lung carcinoma cells. Gene Ther. 29, 357–367 (2022).

doi: 10.1038/s41434-022-00324-7 pubmed: 35314779 pmcid: 9203268

Thomas, J. D. et al. RNA isoform screens uncover the essentiality and tumor-suppressor activity of ultraconserved poison exons. Nat. Genet. 52, 84–94 (2020). This work reveals tumour-suppressive roles for poison exons.

doi: 10.1038/s41588-019-0555-z pubmed: 31911676 pmcid: 6962552

Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465–478 (2019).

doi: 10.1038/s41568-019-0162-4 pubmed: 31278396 pmcid: 6874891

Vauchy, C. et al. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. Int. J. Cancer 137, 116–126 (2015).

doi: 10.1002/ijc.29366 pubmed: 25449106

Oka, M. et al. Aberrant splicing isoforms detected by full-length transcriptome sequencing as transcripts of potential neoantigens in non-small cell lung cancer. Genome Biol. 22, 9 (2021).

doi: 10.1186/s13059-020-02240-8 pubmed: 33397462 pmcid: 7780684

Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

doi: 10.1056/NEJMoa1406498 pubmed: 25409260 pmcid: 4315319

Frankiw, L., Baltimore, D. & Li, G. Alternative mRNA splicing in cancer immunotherapy. Nat. Rev. Immunol. 19, 675–687 (2019).

doi: 10.1038/s41577-019-0195-7 pubmed: 31363190

Slansky, J. E. & Spellman, P. T. Alternative splicing in tumors—a path to immunogenicity? N. Engl. J. Med. 380, 877–880 (2019).

doi: 10.1056/NEJMcibr1814237 pubmed: 30811916

Hoyos, L. E. & Abdel-Wahab, O. Cancer-specific splicing changes and the potential for splicing-derived neoantigens. Cancer Cell 34, 181–183 (2018).

doi: 10.1016/j.ccell.2018.07.008 pubmed: 30107172 pmcid: 6614861

Bowling, E. A. et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell 184, 384–403.e21 (2021). This work shows that inhibition of the SF3b complex triggers antiviral signalling.

doi: 10.1016/j.cell.2020.12.031 pubmed: 33450205 pmcid: 8635244

Lu, S. X. et al. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell 184, 4032–4047.e31 (2021). This work demonstrates that splicing modulation triggers neoantigen production and synergizes with immune checkpoint blockade.

doi: 10.1016/j.cell.2021.05.038 pubmed: 34171309 pmcid: 8684350

De Paoli-Iseppi, R., Gleeson, J. & Clark, M. B. Isoform age—splice isoform profiling using long-read technologies. Front. Mol. Biosci. 8, 711733 (2021).

doi: 10.3389/fmolb.2021.711733 pubmed: 34409069 pmcid: 8364947

Veiga, D. F. T. et al. A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. Sci. Adv. 8, eabg6711 (2022). This work identifies full-length isoforms in primary tumours using LR-seq.

doi: 10.1126/sciadv.abg6711 pubmed: 35044822 pmcid: 8769553

Tian, L. et al. Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. Genome Biol. 22, 310 (2021).

doi: 10.1186/s13059-021-02525-6 pubmed: 34763716 pmcid: 8582192

Gupta, I. et al. Single-cell isoform RNA sequencing characterizes isoforms in thousands of cerebellar cells. Nat. Biotechnol. 36, 1197–1202 (2018).

doi: 10.1038/nbt.4259

Hardwick, S. A. et al. Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue. Nat. Biotechnol. 40, 1082–1092 (2022).

doi: 10.1038/s41587-022-01231-3 pubmed: 35256815 pmcid: 9287170

Joglekar, A. et al. A spatially resolved brain region- and cell type-specific isoform atlas of the postnatal mouse brain. Nat. Commun. 12, 463 (2021).

doi: 10.1038/s41467-020-20343-5 pubmed: 33469025 pmcid: 7815907

Mou, H. et al. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. Genome Biol. 18, 108 (2017).

doi: 10.1186/s13059-017-1237-8 pubmed: 28615073 pmcid: 5470253

Urbanski, L. et al. MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. Cell Rep. 41, 11704 (2022).

doi: 10.1016/j.celrep.2022.111704

Hsu, T. Y. et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature 525, 384–388 (2015). This work identifies a MYC-driven splicing vulnerability.

doi: 10.1038/nature14985 pubmed: 26331541 pmcid: 4831063

Rossbach, O. et al. Auto- and cross-regulation of the hnRNP L proteins by alternative splicing. Mol. Cell Biol. 29, 1442–1451 (2009).

doi: 10.1128/MCB.01689-08 pubmed: 19124611 pmcid: 2648227

Lareau, L. F., Inada, M., Green, R. E., Wengrod, J. C. & Brenner, S. E. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 446, 926–929 (2007). This landmark study identifies conserved poison exons in genes encoding SR proteins.

doi: 10.1038/nature05676 pubmed: 17361132

Ciesla, M. et al. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Mol. Cell 81, 1453–1468.e12 (2021).

doi: 10.1016/j.molcel.2021.01.034 pubmed: 33662273

Kralovicova, J., Moreno, P. M., Cross, N. C., Pego, A. P. & Vorechovsky, I. Antisense oligonucleotides modulating activation of a nonsense-mediated RNA decay switch exon in the ATM gene. Nucleic Acid. Ther. 26, 392–400 (2016).

doi: 10.1089/nat.2016.0635 pubmed: 27658045 pmcid: 5105335

Mercatante, D. R., Bortner, C. D., Cidlowski, J. A. & Kole, R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J. Biol. Chem. 276, 16411–16417 (2001).

doi: 10.1074/jbc.M009256200 pubmed: 11278482

Taylor, J. K., Zhang, Q. Q., Wyatt, J. R. & Dean, N. M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097–1100 (1999).

doi: 10.1038/15079 pubmed: 10545916

Liu, J. et al. Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides. Oncotarget 8, 77567–77585 (2017).

doi: 10.18632/oncotarget.20658 pubmed: 29100409 pmcid: 5652800

Anczuków, O. et al. BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clin. Cancer Res. 18, 4903–4909 (2012).

doi: 10.1158/1078-0432.CCR-12-1100 pubmed: 22753590

Nielsen, T. O., Sorensen, S., Dagnaes-Hansen, F., Kjems, J. & Sorensen, B. S. Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br. J. Cancer 108, 2291–2298 (2013).

doi: 10.1038/bjc.2013.247 pubmed: 23695025 pmcid: 3681029

Li, L. et al. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. Br. J. Cancer 123, 1024–1032 (2020).

doi: 10.1038/s41416-020-0951-2 pubmed: 32581342 pmcid: 7493922

Bruno, I. G., Jin, W. & Cote, G. J. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum. Mol. Genet. 13, 2409–2420 (2004).

doi: 10.1093/hmg/ddh272 pubmed: 15333583

Lin, J. et al. Induced-decay of glycine decarboxylase transcripts as an anticancer therapeutic strategy for non-small-cell lung carcinoma. Mol. Ther. Nucleic Acids 9, 263–273 (2017).

doi: 10.1016/j.omtn.2017.10.001 pubmed: 29246305 pmcid: 5675722

Karras, J. G., McKay, R. A., Lu, T., Dean, N. M. & Monia, B. P. Antisense inhibition of membrane-bound human interleukin-5 receptor-α chain does not affect soluble receptor expression and induces apoptosis in TF-1 cells. Antisense Nucleic Acid. Drug Dev. 10, 347–357 (2000).

doi: 10.1089/oli.1.2000.10.347 pubmed: 11079574

Shieh, J. J., Liu, K. T., Huang, S. W., Chen, Y. J. & Hsieh, T. Y. Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J. Invest. Dermatol. 129, 2497–2506 (2009).

doi: 10.1038/jid.2009.83 pubmed: 19369967

Shiraishi, T., Eysturskarth, J. & Nielsen, P. E. Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron–exon junctions. BMC Cancer 10, 342 (2010).

doi: 10.1186/1471-2407-10-342 pubmed: 20591158 pmcid: 2910690

Dewaele, M. et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J. Clin. Invest. 126, 68–84 (2016).

doi: 10.1172/JCI82534 pubmed: 26595814

Ghigna, C. et al. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol. 7, 495–503 (2010).

doi: 10.4161/rna.7.4.12744 pubmed: 20864806

Zammarchi, F. et al. Antitumorigenic potential of STAT3 alternative splicing modulation. Proc. Natl Acad. Sci. USA 108, 17779–17784 (2011). This work demonstrates that ASOs can be used to manipulate splicing in in vivo cancer models.

doi: 10.1073/pnas.1108482108 pubmed: 22006329 pmcid: 3203802

Izaguirre, D. I. et al. PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. Mol. Carcinog. 51, 895–906 (2012).

doi: 10.1002/mc.20859 pubmed: 21976412

Shen, H., Zheng, X., Luecke, S. & Green, M. R. The U2AF35-related protein Urp contacts the 3′ splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. Genes Dev. 24, 2389–2394 (2010).

doi: 10.1101/gad.1974810 pubmed: 21041408 pmcid: 2964749

Dvinge, H. & Bradley, R. K. Widespread intron retention diversifies most cancer transcriptomes. Genome Med. 7, 45 (2015).

doi: 10.1186/s13073-015-0168-9 pubmed: 26113877 pmcid: 4480902

Mehmood, A. et al. Systematic evaluation of differential splicing tools for RNA-seq studies. Brief. Bioinform 21, 2052–2065 (2020).

doi: 10.1093/bib/bbz126 pubmed: 31802105

Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-seq data. Proc. Natl Acad. Sci. USA 111, 5593–5601 (2014).

doi: 10.1073/pnas.1419161111

Katz, Y., Wang, E. T., Airoldi, E. M. & Burge, C. B. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat. Methods 7, 1009–1015 (2010).

doi: 10.1038/nmeth.1528 pubmed: 21057496 pmcid: 3037023

Vaquero-Garcia, J. et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. eLife 5, 11752 (2016).

doi: 10.7554/eLife.11752

Trincado, J. L. et al. SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions. Genome Biol. 19, 40 (2018).

doi: 10.1186/s13059-018-1417-1 pubmed: 29571299 pmcid: 5866513

Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 50, 151–158 (2018).

doi: 10.1038/s41588-017-0004-9 pubmed: 29229983

Leger, A. et al. RNA modifications detection by comparative Nanopore direct RNA sequencing. Nat. Commun. 12, 7198 (2021).

doi: 10.1038/s41467-021-27393-3 pubmed: 34893601 pmcid: 8664944

He, S. et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01483-z (2022).

doi: 10.1038/s41587-022-01483-z pubmed: 36302989 pmcid: 9931589

RNA splicing dysregulation and the hallmarks of cancer.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Subventions

Informations de copyright

Références

Auteurs

Robert K Bradley (RK)

Olga Anczuków (O)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH